GlaxoSmithKline submits UMEC/VI for approval in EU
Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD).
Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD).
The companies previously announced the submission of a regulatory application in the US on December 18th.
The firms also plan to make submissions for regulatory approval for UMEC monotherapy later this year.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Glaxo's share price rose 0.44% to 1,379.50p by 13:22.
NR
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Landlords ordered to make rental properties more energy efficient by 2030
The government has said rental properties must have a minimum EPC rating of C by 2030. We explain how much it will cost landlords to upgrade their buy-to-let portfolio
By Marc Shoffman Published
-
Primark owner Associated British Foods is an overlooked gem going cheap — should you buy shares?
Associated British Foods, the owner of Primark, is a family-owned business, which means it is passed over by the increasingly popular passive investment funds. That spells opportunity for private investors, says Jamie Ward.
By Jamie Ward Published